Efficacy of Stellate Ganglion Block in Dysphagic Patients With Bulbar Palsy After Ischemic Stroke
Launched by ZENG CHANGHAO · Jan 23, 2024
Trial Information
Current as of May 19, 2025
Withdrawn
Keywords
ClinConnect Summary
Palliation of dysphagia in patients with bulbar palsy after ischemic stroke continues to be a challenge.This is a randomized controlled study, including dysphagic patients with bulbar palsy after ischemic stroke who were received in the department of rehabilitation medicine in 3 hospitals in China. All patients are randomly allocated to the observation group or the control group. Both groups are provided with comprehensive rehabilitation. Besides, the observation group additionally undergoes the stellate ganglion block. At admission and after 20-day treatment, video fluoroscopic swallowing ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with ischemic stroke according to the diagnostic criteria, with the stroke occurring in the medulla oblongata and diagnosed as bulbar palsy.
- • Upper Esophageal Sphincter did not open or opened ineffectively, with food residue or aspiration, revealed by Videofluoroscopic Swallow Study.
- • Age \>18 years.
- • First-time stroke.
- • Steady vital signs,
- • Transferred or admitted to the Department of Rehabilitation Medicine within 15d after onset.
- Exclusion Criteria:
- • The bulbar palsy caused by other diseases, such as neurodegenerative diseases.
- • Pseudobulbar palsy.
- • Complicated with other neurological diseases.
- • Tracheostomy tube inserted.
- • Simultaneously suffering from liver, kidney failure, tumors, or hematological diseases.
- • Dysphagia caused by other possible diseases.
- • Pregnant females.
About Zeng Changhao
Zeng Changhao is a dedicated clinical trial sponsor focused on advancing medical research and innovation through rigorous and ethically conducted clinical studies. With a commitment to improving patient outcomes, Zeng Changhao collaborates with leading healthcare professionals and research institutions to explore novel therapies and treatment modalities. The organization emphasizes transparency, compliance, and patient safety, ensuring that all trials adhere to the highest regulatory standards. Through its strategic partnerships and a patient-centric approach, Zeng Changhao aims to contribute significantly to the development of effective and safe healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Guangzhou, Guangdong, China
Beijing, Beijing, China
Zhengzhou, Henan, China
Zhengzhou, Henan, China
Patients applied
Trial Officials
Nieto Luis, Master
Study Director
Site Coordinator of United Medical Group located in Miami
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported